Pharmaceuticals News and Research

RSS

Lecture to explain science behind modern pharmaceutical products

The science behind the creation of medicines is the subject of a lecture at the University of Greenwich's Medway Campus on Wednesday, April 13.

8 Apr 2011

Strathclyde establishes new EPSRC Centre to improve chemical manufacturing

An EPSRC Centre for revolutionising the way pharmaceuticals and other chemicals are made is being officially launched today.

8 Apr 2011

How the pharmaceutical industry is confronting a changing landscape

News outlets report on strategies and trends regarding research and development as well as drug pricing.

8 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

NAFC honors UT Southwestern nurse with Continence Care Champion Award

The National Association For Continence presented Tamara Dickinson, RN, CURN, CCCN, BCB-PMD, with its Rodney Appell Continence Care Champion Award at the Society of Urologic Nurses and Associates luncheon on March 11, held during the 2011 SUNA Annual Symposium in New Orleans.

8 Apr 2011

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Linda Roberts was puzzled when her favorite food, chocolate ice cream, suddenly did not taste good, and her prized orchids didn't smell nice either. When she began having sudden, severe headaches, she mentioned the changes in taste and smell to her doctor. After several tests, Roberts was diagnosed with a glioblastoma multiforme, the most aggressive form of brain tumor.

8 Apr 2011

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

One-third of senior doctors are still working full time

More than 1 in 10 Canadian physicians is age 65 and older, but many doctors remain active in clinical practice after reaching the traditional retirement age, according to a study released today by the Canadian Institute for Health Information.

8 Apr 2011

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.

8 Apr 2011

CFFT, Vertex collaborate to develop new medicines for cystic fibrosis

Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. today announced they will collaborate on the continued discovery and development of new medicines known as correctors that aim to treat the underlying cause of cystic fibrosis in people with the most common form of the disease.

8 Apr 2011

Opinions: Support antibiotic R&D; foreign aid budget cuts

"The framework for antibiotic discovery, development and approval is broken," Matthew Cooper of the University of Queensland and David Shales, former vice president at Wyeth Pharmaceuticals, write in a Nature comment, calling for "a sustained effort from government and industry to develop new drugs quickly."

8 Apr 2011

IDSA develops plans to combat deadly antibiotic-resistant 'super bugs'

To head off a health care disaster, the Infectious Diseases Society of America has developed a plan to combat deadly antibiotic-resistant "super bugs" and is rolling out the multi-pronged plan today, on World Health Day 2011.

8 Apr 2011

Luminex receives Medical Design Excellence Award for innovative MAGPIX system

Luminex Corporation has won a 2011 Medical Design Excellence Award in the category of In Vitro Diagnostics for its innovative MAGPIX system. Introduced in 2010, MAGPIX is a compact, versatile laboratory analysis platform designed to improve productivity by delivering multiple highly accurate, reproducible results from a single sample.

From Luminex 8 Apr 2011

Zacharon, Pfizer enter research collaboration to develop drugs for orphan diseases

Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.

7 Apr 2011

CoMeD urges UN to ban mercury use in pharmaceuticals

While the United Nations actively questions the use of a vaccine preservative that contains the known neurotoxin mercury, the Coalition for Mercury-Free Drugs, a Maryland-based, non-profit organization, is urging the UN to ban it.

7 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011

Physician's documentation confirms successful treatment of basal cell carcinoma with topical cannabis extract

Cannabis Science, Inc., US biotech company developing pharmaceutical cannabis products. On March 9, 2011 Cannabis Science announced that we would follow up our press release with medical documentation regarding the effectiveness of our cannabis extracts for treating skin cancer as was documented photographically in our earlier press release of February 22, 2011.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011